JP2007520564A5 - - Google Patents

Download PDF

Info

Publication number
JP2007520564A5
JP2007520564A5 JP2006552252A JP2006552252A JP2007520564A5 JP 2007520564 A5 JP2007520564 A5 JP 2007520564A5 JP 2006552252 A JP2006552252 A JP 2006552252A JP 2006552252 A JP2006552252 A JP 2006552252A JP 2007520564 A5 JP2007520564 A5 JP 2007520564A5
Authority
JP
Japan
Prior art keywords
substance
use according
ccx
subject
ckr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006552252A
Other languages
English (en)
Japanese (ja)
Other versions
JP4916889B2 (ja
JP2007520564A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/003521 external-priority patent/WO2005074645A2/en
Publication of JP2007520564A publication Critical patent/JP2007520564A/ja
Publication of JP2007520564A5 publication Critical patent/JP2007520564A5/ja
Application granted granted Critical
Publication of JP4916889B2 publication Critical patent/JP4916889B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006552252A 2004-02-03 2005-02-02 血管新生を調節するための方法および組成物 Expired - Fee Related JP4916889B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US54184904P 2004-02-03 2004-02-03
US60/541,849 2004-02-03
US59895804P 2004-08-04 2004-08-04
US60/598,958 2004-08-04
US62619504P 2004-11-08 2004-11-08
US60/626,195 2004-11-08
PCT/US2005/003521 WO2005074645A2 (en) 2004-02-03 2005-02-02 Methods and compositions for modulating angiogenesis

Publications (3)

Publication Number Publication Date
JP2007520564A JP2007520564A (ja) 2007-07-26
JP2007520564A5 true JP2007520564A5 (cg-RX-API-DMAC7.html) 2008-03-27
JP4916889B2 JP4916889B2 (ja) 2012-04-18

Family

ID=34841735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552252A Expired - Fee Related JP4916889B2 (ja) 2004-02-03 2005-02-02 血管新生を調節するための方法および組成物

Country Status (7)

Country Link
US (1) US20050214287A1 (cg-RX-API-DMAC7.html)
EP (1) EP1715892A4 (cg-RX-API-DMAC7.html)
JP (1) JP4916889B2 (cg-RX-API-DMAC7.html)
AU (1) AU2005209921B2 (cg-RX-API-DMAC7.html)
CA (1) CA2554880A1 (cg-RX-API-DMAC7.html)
IL (1) IL177104A (cg-RX-API-DMAC7.html)
WO (1) WO2005074645A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7417062B2 (en) 2004-09-29 2008-08-26 Chemocentryx, Inc. Substituted arylamides
US20070021484A1 (en) * 2005-06-29 2007-01-25 Chemocentryx, Inc. Substituted N-cinnamyl benzamides
US8088895B2 (en) * 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
JP2009091339A (ja) * 2007-10-12 2009-04-30 Seikagaku Kogyo Co Ltd 関節リウマチの処置剤
KR101701367B1 (ko) * 2008-11-04 2017-02-02 케모센트릭스, 인크. Cxcr7의 모듈레이터
US8853202B2 (en) * 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
US20110014121A1 (en) * 2008-11-04 2011-01-20 Chemocentryx, Inc. Modulators of cxcr7
US20120045393A1 (en) 2009-03-17 2012-02-23 Linder Karen E Lhrh-ii peptide analogs
AU2013352304C1 (en) 2012-11-29 2018-03-22 Chemocentryx, Inc. CXCR7 antagonists
SG11202105889YA (en) 2018-12-12 2021-07-29 Chemocentryx Inc Cxcr7 inhibitors for the treatment of cancer
CN111593022B (zh) * 2018-12-27 2023-10-24 广州溯原生物科技股份有限公司 vMIP-Ⅱ诱导CD8+ T细胞去磷酸化为Tcm及其在药物中的应用
EP4326257A4 (en) 2021-04-19 2025-03-12 ChemoCentryx, Inc. AZETIDINYLACETAMIDES AS CXCR7 INHIBITORS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020166133A1 (en) * 1998-02-10 2002-11-07 Millennium Pharmaceuticals, Inc Neokine protein and nucleic acid molecules and uses therefor
DE69914463T2 (de) * 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
US20020107195A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
NZ524421A (en) * 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
US20040157818A1 (en) * 2001-05-24 2004-08-12 Mikiro Yanaka Cxcr4-antagonistic drugs composed of nitrogen-containing compound
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
ATE427933T1 (de) * 2002-12-20 2009-04-15 Chemocentryx Inc Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
WO2004062591A2 (en) * 2003-01-06 2004-07-29 Oregon Health And Science University Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases

Similar Documents

Publication Publication Date Title
Folkman Role of angiogenesis in tumor growth and metastasis
JP2010500360A5 (cg-RX-API-DMAC7.html)
WO2001027079A3 (en) Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
CA3020400A1 (en) Compositions for topical application of compounds
JP2011503012A5 (cg-RX-API-DMAC7.html)
JP2022188083A5 (cg-RX-API-DMAC7.html)
EP2167038B1 (en) Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
EP2105135A3 (en) Pharmaceutical compositions for treating cancer
Li et al. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors
HRP20200117T1 (hr) Nukleinske kiseline koje se vežu na sdf-1 i njihova upotreba
JP2011527301A5 (cg-RX-API-DMAC7.html)
EA200100799A1 (ru) Антагонисты фактора опухолевого некроза и их применение при эндометриозе
RU2018140900A (ru) Семаглутид при сердечно-сосудистых состояниях
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
Jiang et al. Anti-CCL21 antibody attenuates infarct size and improves cardiac remodeling after myocardial infarction
ZA202204624B (en) Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
Choi New antiresorptive therapies for postmenopausal osteoporosis
Wang et al. Simultaneous targeting of oxidative stress and fibrosis reverses cardiomyopathy‐induced ventricular remodelling and dysfunction
Vaisitti et al. Vls-101 is a novel therapeutic antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) in Richter's syndrome (RS)
Szatmary et al. The Role of Cytokines and Inflammation in the Genesis of Experimental Pancreatitis.
ES2657949T3 (es) KGF/FGF7 para uso en el tratamiento de la atrofia vaginal inducida por la quimioterapia
Banyra et al. Renal cell carcinoma: how to hit the targets?
WO2004007557A3 (en) Tf antagonist
Oratz et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma